Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-116-0 | CAS number: 2156592-45-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The acute oral LD50 of (Z)-4-[C11-13 (branched) alkylamino]-4-oxo-2-butenoic acid after single oral administration to female rats is > 2000 mg/kg bw.
The acute dermal LD50 of (Z)-4-[C11-13 (branched) alkylamino]-4-oxo-2-butenoic acid after single dermal application in male and female rats is > 2000 mg/kg bw.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
Acute oral toxicity
In a GLP compliant study, according to OECD guideline 423, the acute oral toxicity of (Z)-4-[C11-13 (branched) alkylamino]-4-oxo-2-butenoic acid following a single oral administration in female Wistar rats was investigated (Bioassay, 2012). Two groups of fasted animals (3/group) were treated by gavage with (Z)-4-[C11-13 (branched) alkylamino]-4-oxo-2-butenoic acid without a vehicle at a dose level of 2000 mg/kg bw and observed for 14 days. All animals survived until the end of the study period. The following clinical signs were observed: Impaired general state in five animals, dyspnoea in five animals, piloerection in five animals, exsiccosis in one animal, reduced feces in one animal. The mean body weight in both administration groups increased within the normal range during the first post-exposure week, but remained constant during the second week in the second test group only. There were no macroscopic pathological findings in the animals sacrificed at the end of the observation period. The acute oral LD50of (Z)-4-[C11-13 (branched) alkylamino]-4-oxo-2-butenoic acid after single oral administration to female rats is > 2000 mg/kg bw.
Acute dermal toxicity
In a GLP compliant study, according to OECD guideline 402, the acute dermal toxicity of (Z)-4-[C11-13 (branched) alkylamino]-4-oxo-2-butenoic acid following a single dermal application in male and female Wistar rats was investigated (Bioassay, 2012). A group animals (5/sex) was dermally exposed to (Z)-4-[C11-13 (branched) alkylamino]-4-oxo-2-butenoic acid without a vehicle at a dose level of 2000 mg/kg bw for 24 hours under semi-occlusive dressing and observed for 14 days. All animals survived until the end of the study period. There were no signs of systemic toxicity. The following test item-related local effects were recorded during the course of the study: very slight to moderate erythema (grade 1 to 3), very slight to slight edema (grade 1 to 2), incrustations and scaling. The mean body weight of the male animals increased within the normal range throughout the study period. The mean body weight of the lightweight female animals did not significantly change during the first post-exposure observation week, probably due to the bandage procedure, but increased during the second week within the normal range. No macroscopic pathologic abnormalities were noted in the animals examined at the end of the study. The acute dermal LD50of (Z)-4-[C11-13 (branched) alkylamino]-4-oxo-2-butenoic acid after single dermal application in male and female rats is > 2000 mg/kg bw.
Justification for classification or non-classification
Based on the available acute oral and dermal toxicity studies, the substance was neither classified according to Directive 67/548/EEC nor according to CLP
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.